These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Role of imaging test with radionuclides in the diagnosis and treatment of pheochromocytomas and paragangliomas. Araujo-Castro M; Pascual-Corrales E; Alonso-Gordoa T; Molina-Cerrillo J; Martínez Lorca A Endocrinol Diabetes Nutr (Engl Ed); 2022 Oct; 69(8):614-628. PubMed ID: 36402734 [TBL] [Abstract][Full Text] [Related]
5. Systemic Radiopharmaceutical Therapy of Pheochromocytoma and Paraganglioma. Carrasquillo JA; Chen CC; Jha A; Pacak K; Pryma DA; Lin FI J Nucl Med; 2021 Sep; 62(9):1192-1199. PubMed ID: 34475242 [TBL] [Abstract][Full Text] [Related]
6. Response to targeted radionuclide therapy with [ Prado-Wohlwend S; Del Olmo-García MI; Bello-Arques P; Merino-Torres JF Front Endocrinol (Lausanne); 2022; 13():957172. PubMed ID: 36339441 [TBL] [Abstract][Full Text] [Related]
7. Neuroendocrine Tumor Theranostics: An Update and Emerging Applications in Clinical Practice. Sheikhbahaei S; Sadaghiani MS; Rowe SP; Solnes LB AJR Am J Roentgenol; 2021 Aug; 217(2):495-506. PubMed ID: 34076455 [No Abstract] [Full Text] [Related]
8. I-131 metaiodobenzylguanidine therapy is a significant treatment option for pheochromocytoma and paraganglioma. Zhang X; Wakabayashi H; Kayano D; Inaki A; Kinuya S Nuklearmedizin; 2022 Jun; 61(3):231-239. PubMed ID: 35668668 [TBL] [Abstract][Full Text] [Related]
9. Effects and safety of ¹³¹I-metaiodobenzylguanidine (MIBG) radiotherapy in malignant neuroendocrine tumors: results from a multicenter observational registry. Yoshinaga K; Oriuchi N; Wakabayashi H; Tomiyama Y; Jinguji M; Higuchi T; Kayano D; Fukuoka M; Inaki A; Toratani A; Okamoto S; Shiga T; Ito YM; Nakajo M; Nakajo M; Kinuya S; ; ; Endocr J; 2014; 61(12):1171-80. PubMed ID: 25214026 [TBL] [Abstract][Full Text] [Related]
10. 131I-metaiodobenzylguanidine and peptide receptor radionuclide therapy in pheochromocytoma and paraganglioma. Jungels C; Karfis I Curr Opin Oncol; 2021 Jan; 33(1):33-39. PubMed ID: 33093336 [TBL] [Abstract][Full Text] [Related]
11. Prognostic value of [ Takenaka J; Watanabe S; Abe T; Hirata K; Uchiyama Y; Kimura R; Shinohara N; Kudo K Ann Nucl Med; 2023 Jan; 37(1):10-17. PubMed ID: 36301465 [TBL] [Abstract][Full Text] [Related]
12. Iodine-131 metaiodobenzylguanidine (I-131 MIBG) diagnosis and therapy of pheochromocytoma and paraganglioma: current problems, critical issues and presentation of a sample case. Castellani MR; Aktolun C; Buzzoni R; Seregni E; Chiesa C; Maccauro M; Aliberti GL; Vellani C; Lorenzoni A; Bombardieri E Q J Nucl Med Mol Imaging; 2013 Jun; 57(2):146-52. PubMed ID: 23822990 [TBL] [Abstract][Full Text] [Related]
13. Specific binding and uptake of 131I-MIBG and 111In-octreotide in metastatic paraganglioma--tools for choice of radionuclide therapy. Spetz J; Dalmo J; Nilsson O; Wängberg B; Ahlman H; Forssell-Aronsson E Horm Metab Res; 2012 May; 44(5):400-4. PubMed ID: 22566195 [TBL] [Abstract][Full Text] [Related]
14. A phase I clinical trial for [ Inaki A; Yoshimura K; Murayama T; Imai Y; Kuribayashi Y; Higuchi T; Jinguji M; Shiga T; Kinuya S J Med Invest; 2017; 64(3.4):205-209. PubMed ID: 28954983 [TBL] [Abstract][Full Text] [Related]
15. Peptide receptor radionuclide therapy with 177Lu- or 90Y-SSTR peptides in malignant pheochromocytomas (PCCs) and paragangliomas (PGLs): results from a single institutional retrospective analysis. Rubino M; Di Stasio GD; Bodei L; Papi S; Rocca PA; Ferrari ME; Fodor CI; Bagnardi V; Frassoni S; Mei R; Fazio N; Ceci F; Grana CM Endocrine; 2024 May; 84(2):704-710. PubMed ID: 38324106 [TBL] [Abstract][Full Text] [Related]
16. Recent Advances in Radiopharmaceutical Theranostics of Pheochromocytoma and Paraganglioma. Zhang X; Wakabayashi H; Hiromasa T; Kayano D; Kinuya S Semin Nucl Med; 2023 Jul; 53(4):503-516. PubMed ID: 36641337 [TBL] [Abstract][Full Text] [Related]
17. Molecular imaging and theranostic approaches in pheochromocytoma and paraganglioma. Taïeb D; Pacak K Cell Tissue Res; 2018 May; 372(2):393-401. PubMed ID: 29450723 [TBL] [Abstract][Full Text] [Related]
18. I-131 Metaiodobenzylguanidine Therapy of Pheochromocytoma and Paraganglioma. Carrasquillo JA; Pandit-Taskar N; Chen CC Semin Nucl Med; 2016 May; 46(3):203-14. PubMed ID: 27067501 [TBL] [Abstract][Full Text] [Related]
19. Long-Term Outcomes of 125 Patients With Metastatic Pheochromocytoma or Paraganglioma Treated With 131-I MIBG. Thorpe MP; Kane A; Zhu J; Morse MA; Wong T; Borges-Neto S J Clin Endocrinol Metab; 2020 Mar; 105(3):e494-501. PubMed ID: 31614368 [TBL] [Abstract][Full Text] [Related]
20. Detection and treatment of pheochromocytomas and paragangliomas: current standing of MIBG scintigraphy and future role of PET imaging. Havekes B; Lai EW; Corssmit EP; Romijn JA; Timmers HJ; Pacak K Q J Nucl Med Mol Imaging; 2008 Dec; 52(4):419-29. PubMed ID: 19088695 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]